An orally administered PCSK9 has always been a race.
https://www.jacc.org/doi/10.1016/j.jacc.2023.02.018
Merck has put this through a phase 1 AND now a phase 2 while NYR have been pissing about, still preclinical.
They had a 1-2 year window and it is likely they have blown it.
I don't have much skin in this game, it's really just a bit of fun now. I'm fine holding to see how it plays out. There is still a slim chance of a payout.
Ann: Brain Injury Program Preclinical Development Update, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.29M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8250 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.5¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.12pm 03/07/2024 (20 minute delay) ? |
| NYR (ASX) Chart |
Day chart unavailable